Grufity logoGrufity logo

TPTX

Delayed

Turning Point Therapeutics Inc

TPTX Stock Price

RSI Chart

Valuation

Market Cap

3.8B

Price/Earnings

-11.12

Price/Sales

123.46

Price/Cashflow

-14.67

Price/Sales

Profitability

Return on Equity

-43.16%

Return on Assets

-40.59%

Fundamentals

Revenue

Revenue (TTM)

30.8M

Revenue Y/Y

-97.7%

Revenue Q/Q

100%

Earnings

Earnings (TTM)

-342.3M

Earnings Y/Y

-118.73%

Earnings Q/Q

-65.34%

Price Action

Last 7 days

1.3%

Last 30 days

1.8%

Last 90 days

121.4%

Trailing 12 Months

13.9%

Financial Health

Current Ratio

16.83

Investor Care

Shares Dilution (1Y)

1.35%

Diluted EPS (TTM)

-6.91

Peers (Alternatives to Turning Point Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
13.24% 45.49%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
13.13% -41.64%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
3.50% 20.88%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
3.66% 57.19%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
9.35% 28.19%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
9.82% 47.16%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
11.31% 51.76%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-3.30% 6.13%
-18.85
63.29
26.15% -23.38%
3.8B
-
48.10% -29.78%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
6.14% -50.33%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-1.03% -49.23%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
27.64% 144.62%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
12.76% -3.22%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
42.27% -60.18%
-1.4
4.57
-43.57% -69.06%
16.0M
-
3.64% -84.06%
-0.46
19.11
-77.61% 5.14%

Financials for Turning Point Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
RevenueNaN%nullnull314355
Operating Expenses22.1%346283269238215
  S&GA Expenses26.9%9776766962
  R&D Expenses20.4%249207193169152
Net Income-24.3%-342.31-275.49-236.55-205.48-156.86
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-10.2%8439391,0031,0591,103
  Current Assets-10.3%8329279921,0471,091
    Cash Equivalents-6.3%290310428404426
  Net PPE30.2%54443
  Current Liabilities8.5%4946473932
Shareholder's Equity-11.0%7938919541,0171,068
  Retained Earnings-20.8%-714.26-591.17-516.73-438.28-371.95
  Additional Paid-In Capital1.8%1,5141,4881,4721,4561,439
Accumulated Depreciation13.4%33322
Shares Outstanding0.4%5050504949
Float-3,673----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-32.0%-259,445.00-196,534.00-153,885.00-133,180.00-89,700.00
  Share Based Compensation7.1%60,38456,36858,55754,19748,967
Cashflow From Investing355.3%109,19223,9815,462-240,737.00-418,552.00
Cashflow From Financing-2.5%14,35414,72124,004467,572465,587

Risks

What is the probability of a big loss on TPTX?

87.5%


Probability that Turning Point Therapeutics stock will be more than 20% underwater in next one year

84.1%


Probability that Turning Point Therapeutics stock will be more than 30% underwater in next one year.

67.6%


Probability that Turning Point Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TPTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Turning Point Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on TPTX

21.5%


3-Year Cumulative Returns

Which funds bought or sold TPTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
Mint Tower Capital Management B.V.
SOLD OFF
-100
-963,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
SOLD OFF
-100
-4,333,000
-
-%
2022-11-17
Telemetry Investments, L.L.C.
SOLD OFF
-100
-376,000
-
-%
2022-11-17
CENTRAL TRUST Co
SOLD OFF
-100
-1,000
-
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-15,000
-
-%
2022-11-16
Neo Ivy Capital Management
SOLD OFF
-100
-19,000
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SA
SOLD OFF
-100
-855,367
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
SOLD OFF
-100
-442,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
ALGERT GLOBAL LLC
SOLD OFF
-100
-855,000
-
-%

1–10 of 44

Latest Funds Activity

Are funds buying TPTX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own TPTX

Turning Point Therapeutics News

GuruFocus.com

Birchview Capital, LP Buys 3,.6 days ago

U.S News & World Report Money

TPTX Fair Value

Recent SEC filings of Turning Point Therapeutics

View All Filings
Date Filed Form Type Document
Aug 29, 2022
15-12G
15-12G

Latest Insider Trading transactions for TPTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-17
Alles Mark J
GIVEN BACK TO IS
-152,000
76
-2,000
-
2022-08-17
TOMBESI PAOLO
GIVEN BACK TO IS
-2,263,130
76
-29,778
EVP & Chief Financial Officer
2022-08-17
Countouriotis Athena
GIVEN BACK TO IS
-8,432,880
76
-110,959
President & CEO
2022-08-17
Hirmand Mohammad
GIVEN BACK TO IS
-3,137,580
76
-41,284
EVP and Chief Medical Officer
2022-08-17
Sabus Steve M
GIVEN BACK TO IS
-2,786,690
76
-36,667
SVP & Chief Commercial Officer
2022-08-17
George Simeon
GIVEN BACK TO IS
-171,278,000
76
-2,253,660
-
2022-08-17
Sun Brian
GIVEN BACK TO IS
-3,420,000
76
-45,000
SVP & General Counsel
2022-07-27
TOMBESI PAOLO
SOLD
-88,654
74.94
-1,183
EVP & Chief Financial Officer
2022-05-31
Sabus Steve M
ACQUIRED
-
-
36,667
SVP & Chief Commercial Officer
2022-04-11
Sun Brian
ACQUIRED
-
-
45,000
SVP & General Counsel

1–10 of 50

Athena M. Countouriotis
250
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

TPTX Income Statement

2022-06-30
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]    
Revenue$ 119$ 5,164$ 548$ 30,369
Operating expenses:    
Research and development86,78844,650141,83885,913
General and administrative37,69517,17158,00937,162
Total operating expenses124,48361,821199,847123,075
Loss from operations(124,364)(56,657)(199,299)(92,706)
Other income, net1,2763841,766929
Net loss(123,088)(56,273)(197,533)(91,777)
Unrealized (loss)/gain on marketable securities, net of tax(1,522)(22)(5,640)(208)
Comprehensive loss$ (124,610)$ (56,295)$ (203,173)$ (91,985)
Net loss per share, basic$ (2.48)$ (1.14)$ (3.98)$ (1.87)
Net loss per share, diluted$ (2.48)$ (1.14)$ (3.98)$ (1.87)
Weighted-average common shares outstanding, basic49,702,86049,204,42549,657,42649,063,298
Weighted-average common shares outstanding, diluted49,702,86049,204,42549,657,42649,063,298

TPTX Balance Sheet

2022-06-30
Condensed Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 290,147$ 427,879
Marketable securities528,139553,703
Prepaid and other current assets13,38110,880
Total current assets831,667992,462
Property and equipment, net5,0463,822
Right-of-use lease assets4,5835,158
Other assets2,0392,021
Total assets843,3351,003,463
Current liabilities:  
Accounts payable7,9345,656
Accrued expenses and other current liabilities25,56825,300
Accrued compensation11,87412,503
Current portion of operating lease liabilities4,0473,630
Total current liabilities49,42347,089
Operating lease liabilities, long-term8901,949
Commitments and contingencies (Note 8)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2022 and December 31, 2021, zero shares outstanding at June 30, 2022 and December 31, 202100
Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2022 and December 31, 2021; 49,885,036 and 49,582,638 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively55
Additional paid-in capital1,514,1911,472,421
Accumulated other comprehensive (loss)/income(6,914)(1,274)
Accumulated deficit(714,260)(516,727)
Total stockholders' equity793,022954,425
Total liabilities and stockholders’ equity$ 843,335$ 1,003,463